COMPARATIVE EFFECTS OF DOXORUBICIN AND 4'-EPIDOXORUBICIN ON NUCLEIC-ACID METABOLISM AND CYTOTOXICITY IN A HUMAN TUMOR-CELL LINE

被引:14
作者
CANTONI, O
SESTILI, P
CATTABENI, F
GERONI, C
GIULIANI, F
机构
[1] UNIV URBINO,CTR FARMACOL ONCOL SPERIMENTALE,I-61029 URBINO,ITALY
[2] FARMITALIA CARLO ERBA SPA,MILAN,ITALY
关键词
D O I
10.1007/BF00689275
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The effects of 4′-epi-doxorubicin (4′E-Dx) and doxorubicin (Dx) on cell survival were investigated after treatments for 1 or 24 h. It was found that after short-term exposure, 4′E-Dx causes a higher level of killing than Dx, whereas a similar cytotoxic response is detectable after 24 h. Under the same experimental conditions (treatment for 1 or 24 h) at equimolar concentrations, the two anthracyclines were equally inhibitory to DNA or RNA synthesis. Both the degree and the rate of induction of DNA strand breakage over a 1-h drug exposure were higher for 4′E-Dx than for Dx. These data were related to results of experiments carried out to investigate the rates of uptake and egress of the anthracyclines. From this study we concluded that no relationship can be established between the cytotoxicity of 4′E-Dx and Dx and their ability to inhibit DNA and RNA synthesis. In addition, the different DNA-damaging action of the two drugs does not appear to be solely dependent on the different rates of cellular uptake. © 1990 Springer-Verlag.
引用
收藏
页码:47 / 51
页数:5
相关论文
共 18 条
[1]   SYNTHESIS AND ANTITUMOR PROPERTIES OF NEW GLYCOSIDES OF DAUNOMYCINONE AND ADRIAMYCINONE [J].
ARCAMONE, F ;
PENCO, S ;
VIGEVANI, A ;
REDAELLI, S ;
FRANCHI, G ;
DIMARCO, A ;
CASAZZA, AM ;
DASDIA, T ;
FORMELLI, F ;
NECCO, A ;
SORANZO, C .
JOURNAL OF MEDICINAL CHEMISTRY, 1975, 18 (07) :703-707
[2]  
CANTONI O, 1985, IRCS MED SCI-BIOCHEM, V13, P248
[3]   CELLULAR AND MOLECULAR PHARMACOLOGY OF 4'-EPIDOXORUBICIN IN HELA-CELLS - COMPARISON WITH ITS PARENT DRUG, DOXORUBICIN [J].
CANTONI, O ;
SESTILI, P ;
CATTABENI, F ;
GERONI, C ;
GRANDI, M ;
GIULIANI, FC .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1989, 115 (04) :373-378
[4]  
CANTONI O, 1983, MOL PHARMACOL, V24, P84
[5]  
CASAZZA AM, 1978, CURRENT CHEMOTHERAPY, P1257
[6]  
CASAZZA AM, 1980, ANTHRACYCLINES CURRE, P405
[7]  
CROOKE ST, 1978, MOL PHARMACOL, V14, P290
[8]  
Friedberg E. C., 1981, DNA REPAIR LAB MANUA, P379
[9]  
GLAZER RI, 1982, CANCER RES, V42, P117
[10]  
JOHNSTON JB, 1983, CANCER RES, V43, P1044